Show Summary Details
Page of

Levetiracetam, piracetam, and brivaracetam 

Levetiracetam, piracetam, and brivaracetam
Levetiracetam, piracetam, and brivaracetam

Andrea E. Cavanna

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 11 July 2020

Levetiracetam is a third-generation antiepileptic drug characterized by a wide range of antiepileptic indications, with a very good interaction profile in polytherapy. Levetiracetam has an acceptable behavioural tolerability profile, but limited potential for psychiatric uses. Behavioural adverse events (irritability and emotional lability) are often reported by patients with epilepsy taking levetiracetam; psychotic symptoms and episodes of severe aggression have occasionally been reported. Initial reports suggesting a possible role for levetiracetam in the treatment of bipolar depression and anxiety disorders have not been confirmed by the findings of controlled trials. Two other pyrrolidone derivatives chemically related to levetiracetam, the nootropic drug piracetam and the third-generation antiepileptic drug brivaracetam, do not have psychiatric uses.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.